Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 13/20 | 0.51 |
| ▸ | LTA4H | P09960 | 5/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22457757 | 0.96 | ACE (0.55) | ACELTA4HCMA1LMNAACE2 | |
| SCHEMBL6438312 | 0.96 | ACE (0.55) | ACELTA4HCMA1LMNAACE2 | |
| SCHEMBL7377534 | 0.93 | LTA4H (0.52) | ACELTA4HCMA1LMNAACE2 | |
| SCHEMBL22457523 | 0.89 | KLK5 (0.44) | ACECMA1 | |
| SCHEMBL28510339 | 0.87 | ACE (0.58) | ACELMNA | |
| SCHEMBL28510341 | 0.87 | ACE (0.58) | ACELMNA | |
| SCHEMBL28510337 | 0.87 | ACE (0.58) | ACELMNA | |
| SCHEMBL8706477 | 0.85 | ACE (0.67) | ACECMA1ACE2 | |
| SCHEMBL22457752 | 0.85 | KLK5 (0.47) | ACELTA4HCMA1 | |
| SCHEMBL24435890 | 0.84 | ACE (0.60) | ACECMA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| WO-2020189621-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | 日産化学株式会社 | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | ACE 982/4885LTA4H 1599/4885CMA1 550/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | ACE 982/4885LTA4H 1599/4885CMA1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.